Jump to content

Christos Socrates Mantzoros

From Wikipedia, the free encyclopedia
(Redirected from Christos Mantzoros)
Christos Socrates Mantzoros
Born
Nafplio, Greece
Alma mater
Known forLeptin, Adiponectin
Awards
  • Endocrine Society’s Outstanding Clinical Investigator Award (2018)
  • E.V. McCollum Award (2020)
  • Gerald Reaven, Distinguished Leader in Insulin Resistance Award (2022)
Scientific career
FieldsEndocrinology, Diabetes, Metabolism
InstitutionsHarvard Medical School, Beth Israel Deaconess Medical Center
Websitewww.bidmc.org/research/research-by-department/medicine/endocrinology/laboratories/mantzoros-lab

Christos Socrates Mantzoros is a Greek-born American physician-scientist, practicing internist-endocrinologist, teacher and researcher. He is a professor of medicine at Harvard Medical School and an adjunct professor at Boston University School of Medicine. He currently serves as the chief of endocrinology, diabetes and metabolism at the VA Boston Healthcare System, where he created de novo a leading academic division true to its tripartite mission and as the founding director of human nutrition at Beth Israel Deaconess Medical Center (BIDMC), Harvard Medical School. Finally, he holds the editor-in-chief position of the journal Metabolism: Clinical and Experimental.

Mantzoros previously served as a professor of environmental health at the Harvard School of Public Health, associate fellowship program director at BIDMC, and later as the endocrinology, diabetes, and metabolism founding fellowship program director at the Boston VA Healthcare System.

He has given more than 600 lectures nationally and internationally on endocrinology and obesity. His research has resulted in more than 1.000 publications in total, i.e. 700 publications under his name in Medline in addition to more than 200 publications under the collaborative Look Ahead Research Group and more than 290 chapters and reviews or editorials. His work has received more than 96,000 citations, with an h-index of 160 and an i10-index of 643 (Google Scholar).[1][2]

Personal

[edit]

Christos S. Mantzoros was born in Nafplio, Greece, and graduated with MD and received a DSc from the University of Athens Medical School. He completed a residency in internal medicine at Wayne State University and a fellowship in endocrinology, metabolism and diabetes as well as clinical nutrition at the Longwood Training Program (Beth Israel Deaconess Medical Center, Brigham and Women’s Hospital, and Joslin Diabetes Center) of Harvard Medical School. He also received master's degrees in clinical epidemiology from the Harvard School of Public Health and clinical investigation from Harvard Medical School. He is board certified in internal medicine and in endocrinology, metabolism and diabetes, as well as in clinical nutrition. He went rapidly through the academic hierarchy steps from instructor to full professor of internal medicine at Harvard University within twelve years.

Research

[edit]

His work spans the entire spectrum from animal physiology and molecular biology, through observational, epidemiology studies, to physiology and pharmacokinetic interventional proof-of-concept clinical trials on new therapeutic agents important in the treatment of obesity, diabetes and other metabolic diseases in humans.[3] Mantzoros is known for his groundbreaking work on leptin, adiponectin and the proglucagon family of molecules as well as the relationship between insulin-like growth factor (IGFs) and cancer. Recent major contributions of his research group include the elucidation of the physiological role and potential diagnostic and therapeutic utility of several gastrointestinal hormones, myokines and adipokines (i.e. leptin and adiponectin) in human physiology and pathophysiology.[3][4][5] Leptin has subsequently been approved by the United States Food and Drugs Administration for lipodystrophy and severe insulin resistance accompanied by hyperglycemia and hyperlipidemia.[3] His work has resulted in patents for diagnostic and therapeutic applications and has directly contributed to major pharmaceutical companies’ development of new pharmaceuticals. Currently, he and his team are utilizing various interventions (physiological, pharmacological and dietary) and tools (physiological, hormonal, neurocognitive and neuroimaging, functional MRI) to investigate the role of the human brain and peripheral organs in regulating energy homeostasis, obesity and metabolism, and associated comorbidities e.g. diabetes, NASH, cardiovascular diseases and malignancies.

In 2018, Mantzoros gave a Harvard Medical School Mini Med lecture to teach medical concepts to a lay audience. The lecture was attended by close to 100,000 people from all over the world through live-streaming.[6][7]

Leptin and Adiponectin

[edit]

In the area of leptin, Mantzoros pioneered physiology and pharmacokinetic studies, conducted clinical trials in humans, and discovered its therapeutic potential for humans. He was the first to investigate the normal physiology of leptin in humans, including circadian rhythms and the role of leptin in fasting, neuroendocrine regulation in humans and in relation to body weight.[5][8][9][10][11][12][13] His team has published the only three studies on leptin pharmacokinetics determining leptin doses to be used in humans. Indeed, his research broadened the understanding of the neuroendocrine function of leptin on body weight, energy homeostasis, gender differentiation, immunology and the interaction with other hormones, such as thyroid-stimulating hormone and sex steroids. Observing that extreme leanness, hypothalamic amenorrhea (HA) and lipodystrophy were conditions of hypoleptinemia, he piloted clinical trials to test the efficacy of leptin to treat these conditions, showing that leptin replacement in patients with HA and lipodystrophy resulted in complete normalization of hormone axes and bone density in HA as well as improvements in insulin resistance and metabolic regulation in lipodystrophy.[11][12][14][15][16][17][18][19][20][21] Additionally, he observed that functional changes in how the brain views food occur in subjects with hypoleptinemia and that these can be corrected with leptin replacement.[22] Mantzoros and his team observed that short-term metreleptin treatment enhanced activity in areas detecting the salience and rewarding value of food during fasting. In contrast long-term treatment decreased attention to and the rewarding value of food after feeding. Furthermore, hypothalamic activity is modulated by metreleptin treatment and leptin reduces functional connectivity of the hypothalamus to key feeding-related areas in these hypoleptinemic subjects. These findings expanded the role of leptin from that of a hormone regulating energy expenditure to a hormone important in systemic neuroendocrine regulation. The Mantzoros team subsequently focused on physiology studies to explore and elucidate determinants of adiponectin levels in the circulation as well as the physiological role of adiponectin in humans.[23]

Proglucagon derived peptides

[edit]

More recently, Mantzoros’ interest and studies have been directed towards the physiology and clinical significance of GIP and the proglucagon-derived peptides, including endogenous GLP-1, glucagon-like peptide-2, glucagon, oxyntomodulin, glicentin and major proglucagon fragment, which play a significant role in metabolic homeostasis and weight regulation.[24] Among other physiology and interventional studies, Mantzoros published a randomized control trial which showed that administration of the GLP-1 analog liraglutide to overweight/obese individuals leads to downregulation of other proglucagon-derived molecules, suggesting that normalization of the decreasing levels of several of these molecules may provide additional metabolic and weight loss benefits in the future.[25]

Neuroimaging studies

[edit]

Most recently, Mantzoros has been working on the interplay of hormones and environmental factors to influence the function of brain centers important in energy homeostasis and metabolism and how these may be altered with pharmaceuticals to treat obesity. Focusing on the human brain, he studies the control of eating behaviors as they are affected in obesity in the human cortex.[26] Most significantly, he determined the role of GLP-1 in the human brain. When Mantzoros and his team examined the GLP-1 analog liraglutide in diabetic adults and found that liraglutide was decreasing activation in the brain's cortex, the area that increases control and makes individuals more attentive to what they are eating.[27] This suggests that individuals on liraglutide find highly desirable foods less appealing and that the medication might prove an effective weight loss therapy for people who tend to eat foods as a reward, such as when they are stressed. Even though short-term treatment with GLP-1RAs decreases activation in the insula, putamen, caudate and orbitofrontal cortex (areas of the reward system), which may lead to lower energy intake and may thus contribute to weight loss, the impact of GLP-1RAs on brain activity disappears during long-term treatment, which may also explain the eventual weight-loss plateau observed with these medications.[28] Furthermore, Mantzoros and colleagues examined the serotonin 2c receptor agonist lorcaserin in obese adults and discovered that lorcaserin was decreasing activation in the attention-related parietal and visual cortices in response to highly palatable food cues at 1 week in the fasting state and in the parietal cortex in response to any food cues at 4 weeks in the fed state.[29] Decreases in emotion and salience-related limbic activity, including the insula and amygdala, were attenuated at 4 weeks. In a secondary analysis, they observed that decreases in caloric intake, weight, and BMI correlated with activations in amygdala, parietal and visual cortices at baseline, suggesting that lorcaserin would be of particular benefit to emotional eaters. Recently, Mantzoros’ team performed the first neuroimaging study investigating the association of blood concentration of oxyntomodulin, glicentin and GIP with brain activity in response to food cues.[30] Findings showed that fasting blood levels of GIP were inversely associated with the activation of attention-related areas (visual cortices of the occipital lobe, parietal lobe) and of oxyntomodulin and glicentin with reward-related areas (insula, putamen, caudate for both, and additionally orbitofrontal cortex for glicentin) and the hypothalamus when viewing highly desirable as compared to less desirable food images. These studies have important implications for obesity and future therapeutics.

Non-alcoholic fatty liver disease and steatohepatitis

[edit]

In addition to his work on obesity and diabetes, recognizing the rising burden of NAFLD which currently affects approximately 30% of Americans, Mantzoros has been focusing on unveiling the pathophysiology of the disease as well as developing diagnostic, prognostic and therapeutic tools. Regarding pathophysiology, the Mantzoros group has linked NAFLD with not only central obesity and the hormones leptin and adiponectin[31][32][33][34][35] but also with low skeletal mass, skeletal tissue hormones including activins, follistatins and irisin[36][37] as well as with the quality of the diet and the protective role of Mediterrenenan diet.[38][39] The Mantzoros team using the techniques of omics and supervised learning has developed novel models utilizing a top down approach (instead of the usual candidate molecule approach) i.e.metabolites, lipids, hormones and glycans that can diagnose with high accuracy the presence of NASH, NAFLD or healthy status as well as a model that can diagnose liver fibrosis using lipids.[40][41] In addition to demonstrating the significant role of diet, especially that of Mediterranean diet, and dietary habits in the prevention and management of NAFLD, he has been further focusing on the emerging role of antidiabetic and other medications important in metabolism suggested to be used on the background of medical nutrition and lifestyle modification therapy for the treatment of advanced NASH.[42][43][44][45][46] For all these reasons Mantzoros has proposed that a new and more accurate name for this disease i.e. DAFLD/DASH (Dysmetabolism Associated Fatty Liver Disease / Steatohepatitis) would be much more appropriate. Most recently, Mantzoros, representing the Endrocrine Society, has participated in the working group that published the "call to action" paper inviting primary care physicians and subspecialists to prepare for the epidemic of this prevalent condition and to contribute to screening, diagnosing and treating it in their clinics.[47] This working group subsequently published the 2021 guidelines on diagnosis and treatment. Recently, Mantzoros has proposed a new name and a new classification to replace NAFLD, as an umbrella diagnosis under a pathophysiology-based subclassification of Fatty liver disease (FLD).[48]

Epidemiology of cancer

[edit]

Observing that the incidence of certain cancers increases with the rate of obesity (e.g. cancers which have been linked with obesity such as endometrial, esophageal, breast, etc.), Mantzoros hypothesized that insulin-like growth factor 1 (IGF-1) which is also found at higher levels in obesity and a growth factor might be related to the development of cancer. Indeed, he first confirmed in a case-control study that IGF-1 was linked with prostate cancer.[49][50][51] Later, he confirmed a similar link between IGF-1 and other types of cancers, including thyroid, breast, and others both in case control and prospective epidemiology studies.[52][53][54] This work opened the way for efforts to develop molecules blocking IGF-1 signaling as possible treatments for cancer, currently being tested.

Additionally, observing the links between insulin resistance, inflammation, and sex steroids with central obesity and obesity-related cancers, Mantzoros expanded this research to the molecule adiponectin, hypothesizing that abnormalities in this molecule, caused by abnormal fat deposition in the abdomen, were upstream of all other hormonal and inflammatory abnormalities above. First performing physiology studies in rodents and later in human case-control and prospective cohort studies, his team demonstrated the link between adiponectin and several types of cancer, including breast, colorectal, thyroid, prostate, and others.[52][53][55][56][57][58][59][60][61][62][63][64][65][66][67][68][69][70][71][72][73][74][75][76][77][78][79][80] This work opened the way for efforts to develop molecules blocking IGF-1 signaling as possible treatments for cancer, currently being tested.

The Mantzoros group also demonstrated a direct effect of adiponectin and adiponectin receptors on endometrial and other cancers in humans and started mapping the molecular pathways downstream of adiponectin in malignancies.[61][62] This suggests that adiponectin regulation, which is upstream of insulin resistance and IGFs, may be at the root of obesity-related cancers. Due in large part to this research, adiponectin receptor agonists and/or medications that increase circulating levels of adiponectin are currently being tested as a treatment for cancers related to insulin resistance and central obesity.

Mediterranean Diet

[edit]

Mantzoros also demonstrated that following a Mediterranean Diet, which is high in whole-grain cereals and low-fat dairy products and low consumption of refined cereals, leads to improved levels of adipokines like adiponectin, which decreases insulin resistance, and inflammatory factors like c-reactive protein, and thus leads in the long-term to lower incidence of death from cardiovascular disease and stroke.[81][82][83][84][85][86][87]

Metabolism: Clinical and Experimental

[edit]

Metabolism: Clinical and Experimental is a biomedical journal published by Elsevier related to all aspects of metabolism. Metabolism: Clinical and Experimental publishes studies in humans, animal and cellular models. The journal, one with a long history in the field of metabolism, was in decline for several years until 2010. Mantzoros assumed the position of editor-in-chief for the journal Metabolism: Clinical and Experimental in 2010. Since then, the journal has experienced a higher than 20% growth annually in all metrics and its impact factor more than quadrupled under his leadership (current IF: 13.93). The continuous and significant increase of the impact factor and cite score (4 year impact factor) has placed Metabolism: Clinical and Experimental in the top 3% of endocrinology, diabetes and metabolism. Its cited half-life, or the duration an average paper continues receiving citations, was 9.4 in 2018, placing the journal in the top 5% of its category.[88] The current (2022) journal cite score is 16.5.

Translation of science into tangible clinical benefits

[edit]

Mantzoros consults for several companies as the head of the Mantzoros Consulting, LLC. In 2005, he co-founded Intekrin, Inc. which was later acquired by and merged with Coherus, Inc.[89] These companies are developing a number of biosimilars at several stages of clinical development in humans (one approaching FDA approval) in addition to small molecules for diseases related to insulin resistance (e.g. Diabetes, NAFLD). CHRS-131, just successfully completed Phase II trials in humans for multiple sclerosis.[90] More recently, Mantzoros has co-founded or has contributed developing additional biotech companies.

Teaching and mentoring

[edit]

Mantzoros currently serves as the chief of endocrinology, diabetes and metabolism at the VA Boston Healthcare System and the director of the Human Nutrition Unit at Beth Israel Deaconess Medical Center. He teaches at Harvard Medical School and Boston University School of Medicine. He has closely mentored more than 175 scientists, many of whom are now full professors, two are now CEOs, two are chief medical officers and one is chief scientific officer of pharmaceutical / biotechnology companies, several are vice presidents of biotechnology companies and several others are currently assistant and associate professors, executive directors at pharmaceutical companies or clinicians.

Mantzoros, an active member of the Eastern Orthodox Catholic Church, has served in many roles, including teaching pro bono biomedical ethics at the Hellenic College and Holy Cross School of Theology and serving as a member of the Archdiocesan Advisory Council on Bioethics. He has also served as a board member on the Hellenic College Holy Cross (HCHC) board of trustees.

Awards

[edit]

Mantzoros has received several prestigious awards for his lifetime achievements:

  • 2021 Korean Society of Nutrition Award co-administered with the American Society for Nutrition
  • 2020 Gerald Reaven Distinguished Leader in Insulin Resistance Award by the World Congress on Insulin Resistance, Diabetes and Cardiovascular Disease
  • 2020 American Society for Nutrition E.V. McCollum Award
  • 2018 American Society for Nutrition Robert H. Herman Research Award
  • 2018 European Society of Endocrinology highest distinction, i.e. the Geoffrey Harris Award
  • 2018 Endocrine Society’s Outstanding Clinical Investigator Award
  • 2017 Obesity Society TOPS Award

Other (selected) Awards include:

  • Frontiers in Science Award by the American Association of Clinical Endocrinology
  • Novartis Award in Diabetes and Metabolic Diseases by the American Diabetes Association
  • Lilly Award by the North American Association for the Study of Obesity (the Obesity Society)
  • Mead Johnson Award by the American Society for Nutrition
  • HypoCCS award in Paris, France
  • Wilhelm Friedrich Bessel Award by the Humboldt Foundation of Germany
  • Outstanding Investigator Award by the American Federation of Medical Research
  • Hygeia award by the New England Hellenic Medical and Dental Association
  • Berson Award Lecture by the American Physiological Society (FASEB)
  • BIDMC and Harvard Medical School award for Excellence in Mentoring

Honorary titles

[edit]
  • Four honorary PhDs from medical schools worldwide
  • Three honorary professorships from medical schools worldwide
  • Six visiting professorships from medical schools worldwide
  • The Clinical Nutrition Laboratories of the International Hellenic University have been named the “Christos Mantzoros Clinical Nutrition Laboratories”
  • Mantzoros has been elected a member of ASCI
  • Mantzoros has been elected a Fellow of the American College of Physicians and the American Association of Clinical Endocrinology

References

[edit]
  1. ^ "Pubmed References for Dr. Mantzoros".
  2. ^ "Mantzoros Christos - Google Scholar Citations". scholar.google.com. Retrieved 2019-07-03.
  3. ^ a b c "Christos Mantzoros, MD, DSc, h.c. mult. PhD".
  4. ^ Huh, Joo Young; Panagiotou, Grigorios; Mougios, Vassilis; Brinkoetter, Mary; Vamvini, Maria T; Schneider, Benjamin E; Mantzoros, Christos S (2012). "FNDC5 and irisin in humans: I. Predictors of circulating concentrations in serum and plasma and II. MRNA expression and circulating concentrations in response to weight loss and exercise". Metabolism. 61 (12): 1725–38. doi:10.1016/j.metabol.2012.09.002. PMC 3614417. PMID 23018146.
  5. ^ a b Chrysafi, Pavlina; Perakakis, Nikolaos; Farr, Olivia; Stefanakis, Konstantinos; Peradze, Natia; Sala-Vila, Aleix; Mantzoros, Christos S (2020). "Leptin alters energy intake and fat mass but not energy expenditure in lean subjects". Nature Communications. 11 (1): 5145. Bibcode:2020NatCo..11.5145C. doi:10.1038/s41467-020-18885-9. PMC 7553922. PMID 33051459.
  6. ^ "HMS Mini Med Lectures". Archived from the original on 2018-05-11. Retrieved 2018-05-10.
  7. ^ "Mini Med Lecture Video". YouTube. 9 May 2018.
  8. ^ Mantzoros, Christos S; Moschos, Stergios J (1998). "Leptin: In search of role(s) in human physiology and pathophysiology". Clinical Endocrinology. 49 (5): 551–67. doi:10.1046/j.1365-2265.1998.00571.x. PMID 10197068. S2CID 24019740.
  9. ^ Ahima, R. S; Prabakaran, D; Mantzoros, C; Qu, D; Lowell, B; Maratos-Flier, E; Flier, J. S (1996). "Role of leptin in the neuroendocrine response to fasting". Nature. 382 (6588): 250–2. Bibcode:1996Natur.382..250A. doi:10.1038/382250a0. PMID 8717038. S2CID 4331304.
  10. ^ Chan, Jean L; Heist, Kathleen; Depaoli, Alex M; Veldhuis, Johannes D; Mantzoros, Christos S (2003). "The role of falling leptin levels in the neuroendocrine and metabolic adaptation to short-term starvation in healthy men". Journal of Clinical Investigation. 111 (9): 1409–21. doi:10.1172/JCI17490. PMC 154448. PMID 12727933.
  11. ^ a b Roemmich, James N; Clark, Pamela A; Berr, Stuart S; Mai, Vu; Mantzoros, Christos S; Flier, Jeffrey S; Weltman, Arthur; Rogol, Alan D (1998). "Gender differences in leptin levels during puberty are related to the subcutaneous fat depot and sex steroids". American Journal of Physiology. Endocrinology and Metabolism. 275 (3): E543-51. doi:10.1152/ajpendo.1998.275.3.E543. PMID 9725824.
  12. ^ a b Chan, Jean L; Wong, Shekman L; Mantzoros, Christos S (2008). "Pharmacokinetics of Subcutaneous Recombinant Methionyl Human Leptin Administration in Healthy Subjects in the Fed and Fasting States". Clinical Pharmacokinetics. 47 (11): 753–64. doi:10.2165/00003088-200847110-00006. PMC 2737404. PMID 18840030.
  13. ^ Lee, J. H; Chan, J. L; Yiannakouris, N; Kontogianni, M; Estrada, E; Seip, R; Orlova, C; Mantzoros, C. S (2003). "Circulating resistin levels are not associated with obesity or insulin resistance in humans and are not regulated by fasting or leptin administration: Cross-sectional and interventional studies in normal, insulin-resistant, and diabetic subjects". The Journal of Clinical Endocrinology & Metabolism. 88 (10): 4848–56. doi:10.1210/jc.2003-030519. PMID 14557464.
  14. ^ Welt, C. K; Chan, J. L; Bullen, J; Murphy, R; Smith, P; Depaoli, A. M; Karalis, A; Mantzoros, C. S (2004). "Recombinant human leptin in women with hypothalamic amenorrhea". New England Journal of Medicine. 351 (10): 987–97. doi:10.1056/NEJMoa040388. PMID 15342807.
  15. ^ Matarese, G; Moschos, S; Mantzoros, C. S (2005). "Leptin in immunology". Journal of Immunology. 174 (6): 3137–42. doi:10.4049/jimmunol.174.6.3137. PMID 15749839.
  16. ^ Licinio, Julio; Mantzoros, Christos; Negrão, Anadré B; Cizza, Giovanni; Wong, Ma-Li; Bongiorno, Peter B; Chrousos, George P; Karp, Brian; Allen, Christine; Flier, Jeffrey S; Gold, Philip W (1997). "Human leptin levels are pulsatile and inversely related to pituitary–adrenal function". Nature Medicine. 3 (5): 575–9. doi:10.1038/nm0597-575. PMID 9142131. S2CID 6065035.
  17. ^ Mantzoros, Christos S; Ozata, Metin; Negrao, Andre B; Suchard, Marc A; Ziotopoulou, Mary; Caglayan, Sinan; Elashoff, Robert M; Cogswell, Rebecca J; Negro, Paolo; Liberty, Victoria; Wong, Ma-Li; Veldhuis, Johannes; Ozdemir, I. Caglayan; Gold, Philip W; Flier, Jeffrey S; Licinio, Julio (2001). "Synchronicity of Frequently Sampled Thyrotropin (TSH) and Leptin Concentrations in Healthy Adults and Leptin-Deficient Subjects: Evidence for Possible Partial TSH Regulation by Leptin in Humans". The Journal of Clinical Endocrinology & Metabolism. 86 (7): 3284–91. doi:10.1210/jcem.86.7.7644. PMID 11443202.
  18. ^ Mantzoros, Christos S (2006). "Role of Leptin in Reproduction". Annals of the New York Academy of Sciences. 900: 174–83. doi:10.1111/j.1749-6632.2000.tb06228.x. PMID 10818404. S2CID 23194450.
  19. ^ Mantzoros, Christos; Flier, Jeffrey S; Lesem, Michael D; Brewerton, Timothy D; Jimerson, David C (1997). "Cerebrospinal Fluid Leptin in Anorexia Nervosa: Correlation with Nutritional Status and Potential Role in Resistance to Weight Gain1". The Journal of Clinical Endocrinology & Metabolism. 82 (6): 1845–51. doi:10.1210/jcem.82.6.4006. PMID 9177394.
  20. ^ Chan, Jean L; Mantzoros, Christos S (2005). "Role of leptin in energy-deprivation states: Normal human physiology and clinical implications for hypothalamic amenorrhoea and anorexia nervosa". The Lancet. 366 (9479): 74–85. doi:10.1016/S0140-6736(05)66830-4. PMID 15993236. S2CID 37180870.
  21. ^ Mantzoros, Christos S (2009). "Whither Recombinant Human Leptin Treatment for HIV-Associated Lipoatrophy and the Metabolic Syndrome?". The Journal of Clinical Endocrinology & Metabolism. 94 (4): 1089–1091. doi:10.1210/jc.2009-0340. PMC 2730231. PMID 19349474.
  22. ^ Farr, Olivia M; Fiorenza, Christina; Papageorgiou, Panagiotis; Brinkoetter, Mary; Ziemke, Florencia; Koo, Bang-Bon; Rojas, Rafael; Mantzoros, Christos S (2014). "Leptin Therapy Alters Appetite and Neural Responses to Food Stimuli in Brain Areas of Leptin-Sensitive Subjects Without Altering Brain Structure". The Journal of Clinical Endocrinology & Metabolism. 99 (12): E2529-38. doi:10.1210/jc.2014-2774. PMC 4255115. PMID 25279500.
  23. ^ Ziemke, Florencia; Mantzoros, Christos S (2010). "Adiponectin in insulin resistance: lessons from translational research". The American Journal of Clinical Nutrition. 91 (1): 258S–261S. doi:10.3945/ajcn.2009.28449C. PMC 2793112. PMID 19906806.
  24. ^ Perakakis, Nikolaos; Kokkinos, Alexander; Peradze, Natia; Tentouris, Nikolaos; Ghaly, Wael T; Pilitsi, Elena; Upadhyay, Jagriti; Alexandrou, Andreas; Mantzoros, Christos S (2019). "Circulating levels of gastrointestinal hormones in response to the most common types of bariatric surgery and predictive value for weight loss over one year: Evidence from two independent trials". Metabolism. 101: 153997. doi:10.1016/j.metabol.2019.153997. PMID 31672446. S2CID 209568403.
  25. ^ Kim, Suh H; Abbasi, Fahim; Nachmanoff, Clara; Stefanakis, Konstantinos; Kumar, Ajay; Kalra, Bhanu; Savjani, Gopal; Mantzoros, Christos (2021). "Effect of the glucagon-like peptide-1 analogue liraglutide versus placebo treatment on circulating proglucagon-derived peptides that mediate improvements in body weight, insulin secretion and action: A randomized controlled trial". Diabetes, Obesity & Metabolism. 23 (2): 489–498. doi:10.1111/dom.14242. PMC 7856054. PMID 33140542.
  26. ^ Farr, Olivia M; Li, Chiang-Shan R; Mantzoros, Christos S (2016). "Central nervous system regulation of eating: Insights from human brain imaging". Metabolism. 65 (5): 699–713. doi:10.1016/j.metabol.2016.02.002. PMC 4834455. PMID 27085777.
  27. ^ Farr, Olivia M; Sofopoulos, Michail; Tsoukas, Michael A; Dincer, Fadime; Thakkar, Bindiya; Sahin-Efe, Ayse; Filippaios, Andreas; Bowers, Jennifer; Srnka, Alexandra; Gavrieli, Anna; Ko, Byung-Joon; Liakou, Chrysoula; Kanyuch, Nickole; Tseleni-Balafouta, Sofia; Mantzoros, Christos S (2016). "GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: A crossover, randomised, placebo-controlled trial". Diabetologia. 59 (5): 954–65. doi:10.1007/s00125-016-3874-y. PMC 4826792. PMID 26831302.
  28. ^ Farr, Olivia M; Upadhyay, Jagriti; Rutagengwa, Chelsea; DiPrisco, Bridget; Ranta, Zachary; Adra, Amal; Bapatla, Neha; Douglas, Vivian P; Douglas, Konstantinos A A; Nolen-Doerr, Eric; Mathew, Hannah; Mantzoros, Christos S (2019). "Longer-term liraglutide administration at the highest dose approved for obesity increases reward-related orbitofrontal cortex activation in response to food cues: Implications for plateauing weight loss in response to anti-obesity therapies". Diabetes, Obesity & Metabolism. 21 (11): 2459–2464. doi:10.1111/dom.13827. PMC 6800581. PMID 31282006.
  29. ^ Farr, O. M; Upadhyay, J; Gavrieli, A; Camp, M; Spyrou, N; Kaye, H; Mathew, H; Vamvini, M; Koniaris, A; Kilim, H; Srnka, A; Migdal, A; Mantzoros, C. S (2016). "Lorcaserin Administration Decreases Activation of Brain Centers in Response to Food Cues and These Emotion- and Salience-Related Changes Correlate with Weight Loss Effects: A 4-Week-Long Randomized, Placebo-Controlled, Double-Blind Clinical Trial". Diabetes. 65 (10): 2943–53. doi:10.2337/db16-0635. PMC 5033259. PMID 27385157.
  30. ^ Perakakis, Nikolaos; Farr, Olivia M; Mantzoros, Christos (2021). "Fasting oxyntomodulin, glicentin, and gastric inhibitory polypeptide levels are associated with activation of reward- and attention-related brain centres in response to visual food cues in adults with obesity: A cross-sectional functional MRI study". Diabetes, Obesity & Metabolism. 23 (5): 1202–1207. doi:10.1111/dom.14315. PMID 33417264. S2CID 231194982.
  31. ^ Boutari, Chrysoula; Mantzoros, Christos S (2020). "Adiponectin and leptin in the diagnosis and therapy of NAFLD". Metabolism. 103: 154028. doi:10.1016/j.metabol.2019.154028. PMID 31785257. S2CID 208515556.
  32. ^ Polyzos, Stergios A; Kountouras, Jannis; Mantzoros, Christos S (2016). "Adipokines in nonalcoholic fatty liver disease". Metabolism. 65 (8): 1062–79. doi:10.1016/j.metabol.2015.11.006. PMID 26725002.
  33. ^ Boutari, Chrysoula; Perakakis, Nikolaos; Mantzoros, Christos S (2018). "Association of Adipokines with Development and Progression of Nonalcoholic Fatty Liver Disease". Endocrinology and Metabolism (Seoul, Korea). 33 (1): 33–43. doi:10.3803/EnM.2018.33.1.33. PMC 5874193. PMID 29589386.
  34. ^ Polyzos, Stergios A; Mantzoros, Christos S (2016). "Adiponectin as a target for the treatment of nonalcoholic steatohepatitis with thiazolidinediones: A systematic review". Endocrinology and Metabolism (Seoul, Korea). 65 (9): 1297–306. doi:10.1016/j.metabol.2016.05.013. PMID 27506737.
  35. ^ Polyzos, Stergios A; Perakakis, Nikolaos; Mantzoros, Christos S (2019). "Fatty liver in lipodystrophy: A review with a focus on therapeutic perspectives of adiponectin and/or leptin replacement". Metabolism. 96: 66–82. doi:10.1016/j.metabol.2019.05.001. PMID 31071311. S2CID 195661123.
  36. ^ Polyzos, Stergios A; Kountouras, Jannis; Anastasilakis, Athanasios D; Triantafyllou, Georgios A; Mantzoros, Christos S (2016). "Activin A and follistatin in patients with nonalcoholic fatty liver disease". Metabolism. 65 (10): 1550–8. doi:10.1016/j.metabol.2016.07.009. PMC 5022788. PMID 27621190.
  37. ^ Polyzos, Stergios A; Kountouras, Jannis; Anastasilakis, Athanasios D; Geladari, Eleni V; Mantzoros, Christos S (2014). "Irisin in patients with nonalcoholic fatty liver disease". Metabolism. 63 (2): 207–17. doi:10.1016/j.metabol.2013.09.013. PMID 24140091.
  38. ^ Kouvari, Matina; Boutari, Chrysa; Chrysohoou, Christina D; Fragkopoulou, Elizabeth; Antonopoulou, Smaragdi; Tousoulis, Dimitrios; Pitsavos, Christos; Panagiotakos, Demosthenes B; Mantzoros, Christos S (2021). "Mediterranean diet is inversely associated with steatosis and fibrosis and decreases ten-year diabetes and cardiovascular risk in NAFLD subjects: Results from the ATTICA prospective cohort study". Clinical Nutrition (Edinburgh, Scotland). 40 (5): 3314–3324. doi:10.1016/j.clnu.2020.10.058. PMID 33234342. S2CID 227169217.
  39. ^ Lee, Saehyun; Ko, Byung-Joon; Gong, Younghoon; Han, Kyungdo; Lee, Anna; Han, Byoung-Duck; Yoon, Yeo Joon; Park, Siyoung; Kim, Jung-Hyun; Mantzoros, Christos S (2016). "Self-reported eating speed in relation to non-alcoholic fatty liver disease in adults". European Journal of Nutrition. 55 (1): 327–33. doi:10.1007/s00394-015-0851-z. PMID 25648740. S2CID 36907141.
  40. ^ Perakakis, Nikolaos; Polyzos, Stergios A; Yazdani, Alireza; Sala-Vila, Aleix; Kountouras, Jannis; Anastasilakis, Athanasios D; Mantzoros, Christos S (2019). "Non-invasive diagnosis of non-alcoholic steatohepatitis and fibrosis with the use of omics and supervised learning: A proof of concept study". Metabolism. 101: 1540054. doi:10.1016/j.metabol.2019.154005. PMID 31711876. S2CID 207962497.
  41. ^ Perakakis, Nikolaos; Stefanakis, Constantinos; Mantzoros, Christos S (2020). "The role of omics in the pathophysiology, diagnosis and treatment of non-alcoholic fatty liver disease". Metabolism. 111S: 154320. doi:10.1016/j.metabol.2020.154320. PMC 7377759. PMID 32712221.
  42. ^ Nasiri-Ansari, Narjes; Nikolopoulou, Chrysa; Papoutsi, Katerina D; Kyrou, Ioannis; Mantzoros, Christos S; Kyriakopoulos, Georgios; Chatzigeorgiou, Antonios; Kalotychou, Vassiliki; Randeva, Manpal S; Chatha, Kamaljit; Kontzoglou, Konstantinos; Kaltsas, Gregory; Papavassiliou, Athanasios G; Randeva, Harpal S; Kassi, Eva (2021). "Empagliflozin Attenuates Non-Alcoholic Fatty Liver Disease (NAFLD) in High Fat Diet Fed ApoE (-/-) Mice by Activating Autophagy and Reducing ER Stress and Apoptosis". International Journal of Molecular Sciences. 22 (2): 818. doi:10.3390/ijms22020818. PMC 7829901. PMID 33467546.
  43. ^ Polyzos, Stergios A; Kountouras, Jannis; Mantzoros, Christos S; Polymerou, Vaia; Katsinelos, Panagiotis (2017). "Effects of combined low-dose spironolactone plus vitamin E vs vitamin E monotherapy on insulin resistance, non-invasive indices of steatosis and fibrosis, and adipokine levels in non-alcoholic fatty liver disease: a randomized controlled trial". Diabetes, Obesity & Metabolism. 19 (12): 1805–1809. doi:10.1111/dom.12989. PMID 28452101. S2CID 19982214.
  44. ^ Perakakis, Nikolaos; Stefanakis, Konstantinos; Feigh, Michael; Veidal, Sanne S; Mantzoros, Christos S (2021). "Elafibranor and liraglutide improve differentially liver health and metabolism in a mouse model of non-alcoholic steatohepatitis". Liver International. 41 (8): 1853–1866. doi:10.1111/liv.14888. ISSN 1478-3223. PMID 3788377. S2CID 232430841.
  45. ^ Perakakis, Nikolaos; Chrysafi, Pavlina; Feigh, Michael; Veidal, Sanne S; Mantzoros, Christos S (2021). "Empagliflozin Improves Metabolic and Hepatic Outcomes in a Non-Diabetic Obese Biopsy-Proven Mouse Model of Advanced NASH". International Journal of Molecular Sciences. 22 (12): 6332. doi:10.3390/ijms22126332. PMC 8232001. PMID 34199317.
  46. ^ Athyros, Vasilios G; Alexandrides, Theodore K; Bilianou, Helen; Cholongitas, Evangelos; Doumas, Michael; Ganotakis, Emmanuel S; Goudevenos, John; Elisaf, Moses S; Germanidis, Georgios; Giouleme, Olga; Karagiannis, Asterios; Karvounis, Charalambos; Katsiki, Niki; Kotsis, Vasilios; Kountouras, Jannis; Liberopoulos, Evangelos; Pitsavos, Christos; Polyzos, Stergios; Rallidis, Loukianos S; Richter, Dimitrios; Tsapas, Apostolos G; Tselepis, Alexandros D; Tsioufis, Konstantinos; Tziomalos, Konstantinos; Tzotzas, Themistoklis; Vasiliadis, Themistoklis G; Vlachopoulos, Charalambos; Mikhailidis, Dimitri P; Mantzoros, Christos (2017). "The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement". Metabolism. 71: 17–32. doi:10.1016/j.metabol.2017.02.014. PMID 28521870.
  47. ^ Kanwal, Fasiha; Shubrook, Jay H; Younossi, Zobair; Natarajan, Yamini; Bugianesi, Elisabetta; Rinella, Mary E; Harrison, Stephen A; Mantzoros, Christos; Pfotenhauer, Kim; Klein, Samuel; Eckel, Robert H; Kruger, Davida; El-Serag, Hashem; Cusi, Kenneth (2021). "Preparing for the NASH epidemic: A call to action". Metabolism. 122: 154822. doi:10.1016/j.metabol.2021.154822. hdl:2318/1804575. PMID 34289945. S2CID 236175634.
  48. ^ Valenzuela-Vallejo, Laura; Mantzoros, Christos S. (2022). "Time to transition from a negative nomenclature describing what NAFLD is not, to a novel, pathophysiology-based, umbrella classification of fatty liver disease (FLD)". Metabolism. 134: 155246. doi:10.1016/j.metabol.2022.155246. PMID 35780909. S2CID 250232304.
  49. ^ Wolk, A; Mantzoros, C. S; Andersson, S. O; Bergström, R; Signorello, L. B; Lagiou, P; Adami, H. O; Trichopoulos, D (1998). "Insulin-like growth factor 1 and prostate cancer risk: A population-based, case-control study". Journal of the National Cancer Institute. 90 (12): 911–5. doi:10.1093/jnci/90.12.911. PMID 9637140.
  50. ^ Mantzoros, C. S; Tzonou, A; Signorello, L. B; Stampfer, M; Trichopoulos, D; Adami, H. O (1997). "Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia". British Journal of Cancer. 76 (9): 1115–8. doi:10.1038/bjc.1997.520. PMC 2228109. PMID 9365156.
  51. ^ Wolk, A; Andersson, S. O; Mantzoros, C. S; Trichopoulos, D; Adami, H. O (2000). "Can measurements of IGF-1 and IGFBP-3 improve the sensitivity of prostate-cancer screening?". The Lancet. 356 (9245): 1902–3. doi:10.1016/S0140-6736(00)03266-9. PMID 11130391. S2CID 28845541.
  52. ^ a b Moschos, S. J; Mantzoros, C. S (2002). "The role of the IGF system in cancer: From basic to clinical studies and clinical applications". Oncology. 63 (4): 317–32. doi:10.1159/000066230. PMID 12417786. S2CID 1441480.
  53. ^ a b Pazaitou-Panayiotou, Kalliopi; Panagiotou, Grigorios; Polyzos, Stergios A; Mantzoros, Christos S (2016). "Serum Adiponectin and Insulin-Like Growth Factor 1 in Predominantly Female Patients with Thyroid Cancer: Association with the Histologic Characteristics of the Tumor". Endocrine Practice. 22 (1): 68–75. doi:10.4158/EP15814.OR. PMID 26484409.
  54. ^ Larsson, S. C; Mantzoros, C. S; Wolk, A (2007). "Diabetes mellitus and risk of breast cancer: A meta-analysis". International Journal of Cancer. 121 (4): 856–62. doi:10.1002/ijc.22717. PMID 17397032. S2CID 20752831.
  55. ^ Barb, D; Pazaitou-Panayiotou, K; Mantzoros, C. S (2006). "Adiponectin: A link between obesity and cancer". Expert Opinion on Investigational Drugs. 15 (8): 917–31. doi:10.1517/13543784.15.8.917. PMID 16859394. S2CID 23979628.
  56. ^ Inamura, Kentaro; Song, Mingyang; Jung, Seungyoun; Nishihara, Reiko; Yamauchi, Mai; Lochhead, Paul; Qian, Zhi Rong; Kim, Sun A; Mima, Kosuke; Sukawa, Yasutaka; Masuda, Atsuhiro; Imamura, Yu; Zhang, Xuehong; Pollak, Michael N; Mantzoros, Christos S; Harris, Curtis C; Giovannucci, Edward; Fuchs, Charles S; Cho, Eunyoung; Chan, Andrew T; Wu, Kana; Ogino, Shuji (2015). "Prediagnosis Plasma Adiponectin in Relation to Colorectal Cancer Risk According toKRASMutation Status". Journal of the National Cancer Institute. 108 (4): djv363. doi:10.1093/jnci/djv363. PMC 4668768. PMID 26598515.
  57. ^ Michalakis, Konstantinos; Venihaki, Maria; Mantzoros, Christos; Vazaiou, Andriani; Ilias, Ioannis; Gryparis, Alexandros; Margioris, Andrew N (2015). "In prostate cancer, low adiponectin levels are not associated with insulin resistance". European Journal of Clinical Investigation. 45 (6): 572–8. doi:10.1111/eci.12445. PMID 25833038. S2CID 205093762.
  58. ^ Moon, H.-S; Mantzoros, C. S (2013). "Adiponectin and metformin additively attenuate IL1 -induced malignant potential of colon cancer". Endocrine-Related Cancer. 20 (6): 849–59. doi:10.1530/ERC-13-0240. PMID 24157941.
  59. ^ Dalamaga, Maria; Karmaniolas, Konstantinos; Chamberland, John; Nikolaidou, Athina; Lekka, Antigoni; Dionyssiou-Asteriou, Amalia; Mantzoros, Christos S (2013). "Higher fetuin-A, lower adiponectin and free leptin levels mediate effects of excess body weight on insulin resistance and risk for myelodysplastic syndrome". Metabolism. 62 (12): 1830–9. doi:10.1016/j.metabol.2013.09.007. PMID 24140093.
  60. ^ Kaklamani, Virginia G; Hoffmann, Thomas J; Thornton, Timothy A; Hayes, Geoffrey; Chlebowski, Rowan; Van Horn, Linda; Mantzoros, Christos (2013). "Adiponectin pathway polymorphisms and risk of breast cancer in African Americans and Hispanics in the Women's Health Initiative". Breast Cancer Research and Treatment. 139 (2): 461–8. doi:10.1007/s10549-013-2546-6. PMC 3773607. PMID 23624817.
  61. ^ a b Dalamaga, Maria; Diakopoulos, Kalliope N; Mantzoros, Christos S (2012). "The Role of Adiponectin in Cancer: A Review of Current Evidence". Endocrine Reviews. 33 (4): 547–94. doi:10.1210/er.2011-1015. PMC 3410224. PMID 22547160.
  62. ^ a b Moon, H.-S; Chamberland, J. P; Aronis, K; Tseleni-Balafouta, S; Mantzoros, C. S (2011). "Direct Role of Adiponectin and Adiponectin Receptors in Endometrial Cancer: In Vitro and Ex Vivo Studies in Humans". Molecular Cancer Therapeutics. 10 (12): 2234–43. doi:10.1158/1535-7163.MCT-11-0545. PMC 3237794. PMID 21980131.
  63. ^ Mitsiades, Nicholas; Pazaitou-Panayiotou, Kalliopi; Aronis, Konstantinos N; Moon, Hyun-Seuk; Chamberland, John P; Liu, Xiaowen; Diakopoulos, Kalliope N; Kyttaris, Vasileios; Panagiotou, Vasiliki; Mylvaganam, Geetha; Tseleni-Balafouta, Sofia; Mantzoros, Christos S (2011). "Circulating Adiponectin is Inversely Associated with Risk of Thyroid Cancer:In Vivoandin Vitro Studies". The Journal of Clinical Endocrinology & Metabolism. 96 (12): E2023-8. doi:10.1210/jc.2010-1908. PMC 3232611. PMID 21937620.
  64. ^ Gialamas, Spyros P; Petridou, Eleni Th; Tseleni-Balafouta, Sofia; Spyridopoulos, Themistoklis N; Matsoukis, Ioannis L; Kondi-Pafiti, Agathi; Zografos, George; Mantzoros, Christos S (2011). "Serum adiponectin levels and tissue expression of adiponectin receptors are associated with risk, stage, and grade of colorectal cancer". Metabolism. 60 (11): 1530–8. doi:10.1016/j.metabol.2011.03.020. PMID 21632074.
  65. ^ Petridou, Eleni Th; Sergentanis, Theodoros N; Dessypris, Nick; Vlachantoni, Iris T; Tseleni-Balafouta, Sofia; Pourtsidis, Apostolos; Moschovi, Maria; Polychronopoulou, Sofia; Athanasiadou-Piperopoulou, Fani; Kalmanti, Maria; Mantzoros, Christos S (2009). "Serum Adiponectin As a Predictor of Childhood Non-Hodgkin's Lymphoma: A Nationwide Case-Control Study". Journal of Clinical Oncology. 27 (30): 5049–55. doi:10.1200/JCO.2008.19.7525. PMC 2799057. PMID 19738128.
  66. ^ Dalamaga, Maria; Migdalis, Ilias; Fargnoli, Jessica L; Papadavid, Evangelia; Bloom, Erica; Mitsiades, Nicholas; Karmaniolas, Konstantinos; Pelecanos, Nicolaos; Tseleni-Balafouta, Sofia; Dionyssiou-Asteriou, Amalia; Mantzoros, Christos S (2008). "Pancreatic cancer expresses adiponectin receptors and is associated with hypoleptinemia and hyperadiponectinemia: A case–control study". Cancer Causes & Control. 20 (5): 625–33. doi:10.1007/s10552-008-9273-z. PMC 2720089. PMID 19051043.
  67. ^ Dalamaga, Maria; Karmaniolas, Konstantinos; Panagiotou, Anna; Hsi, Alex; Chamberland, John; Dimas, Cleanthi; Lekka, Antigoni; Mantzoros, Christos S (2008). "Low circulating adiponectin and resistin, but not leptin, levels are associated with multiple myeloma risk: A case–control study". Cancer Causes & Control. 20 (2): 193–9. doi:10.1007/s10552-008-9233-7. PMID 18814045. S2CID 11372840.
  68. ^ Sher, David J; Oh, William K; Jacobus, Susanna; Regan, Meredith M; Lee, Gwo-Shu; Mantzoros, Christos (2008). "Relationship between serum adiponectin and prostate cancer grade". The Prostate. 68 (14): 1592–8. doi:10.1002/pros.20823. PMID 18646046. S2CID 41752707.
  69. ^ Kaklamani, V. G; Sadim, M; Hsi, A; Offit, K; Oddoux, C; Ostrer, H; Ahsan, H; Pasche, B; Mantzoros, C (2008). "Variants of the Adiponectin and Adiponectin Receptor 1 Genes and Breast Cancer Risk". Cancer Research. 68 (9): 3178–84. doi:10.1158/0008-5472.CAN-08-0533. PMC 2685173. PMID 18451143.
  70. ^ Barb, D; Neuwirth, A; Mantzoros, C. S; Balk, S. P (2007). "Adiponectin signals in prostate cancer cells through Akt to activate the mammalian target of rapamycin pathway". Endocrine-Related Cancer. 14 (4): 995–1005. doi:10.1677/ERC-06-0091. PMID 18045951.
  71. ^ Mantzoros, C. S; Trakatelli, M; Gogas, H; Dessypris, N; Stratigos, A; Chrousos, G. P; Petridou, E. T (2007). "Circulating adiponectin levels in relation to melanoma: A case-control study". European Journal of Cancer. 43 (9): 1430–6. doi:10.1016/j.ejca.2007.03.026. PMID 17512191.
  72. ^ Tworoger, S. S; Eliassen, A. H; Kelesidis, T; Colditz, G. A; Willett, W. C; Mantzoros, C. S; Hankinson, S. E (2007). "Plasma adiponectin concentrations and risk of incident breast cancer". The Journal of Clinical Endocrinology & Metabolism. 92 (4): 1510–6. doi:10.1210/jc.2006-1975. PMID 17213279.
  73. ^ Spyridopoulos, T. N; Petridou, E. T; Skalkidou, A; Dessypris, N; Chrousos, G. P; Mantzoros, C. S; Obesity Cancer Oncology Group (2007). "Low adiponectin levels are associated with renal cell carcinoma: A case-control study". International Journal of Cancer. 120 (7): 1573–8. doi:10.1002/ijc.22526. PMID 17205522. S2CID 25292741.
  74. ^ Kelesidis, I; Kelesidis, T; Mantzoros, C. S (2006). "Adiponectin and cancer: A systematic review". British Journal of Cancer. 94 (9): 1221–5. doi:10.1038/sj.bjc.6603051. PMC 2361397. PMID 16570048.
  75. ^ Petridou, E; Mantzoros, C. S; Dessypris, N; Dikalioti, S. K; Trichopoulos, D (2006). "Adiponectin in relation to childhood myeloblastic leukaemia". British Journal of Cancer. 94 (1): 156–60. doi:10.1038/sj.bjc.6602896. PMC 2361080. PMID 16404369.
  76. ^ Wei, E. K; Giovannucci, E; Fuchs, C. S; Willett, W. C; Mantzoros, C. S (2005). "Low plasma adiponectin levels and risk of colorectal cancer in men: A prospective study". Journal of the National Cancer Institute. 97 (22): 1688–94. doi:10.1093/jnci/dji376. PMID 16288122.
  77. ^ Dal Maso, L; Augustin, L. S; Karalis, A; Talamini, R; Franceschi, S; Trichopoulos, D; Mantzoros, C. S; La Vecchia, C (2004). "Circulating adiponectin and endometrial cancer risk". The Journal of Clinical Endocrinology & Metabolism. 89 (3): 1160–3. doi:10.1210/jc.2003-031716. PMID 15001602. S2CID 30271923.
  78. ^ Mantzoros, C; Petridou, E; Dessypris, N; Chavelas, C; Dalamaga, M; Alexe, D. M; Papadiamantis, Y; Markopoulos, C; Spanos, E; Chrousos, G; Trichopoulos, D (2004). "Adiponectin and breast cancer risk". The Journal of Clinical Endocrinology & Metabolism. 89 (3): 1102–7. doi:10.1210/jc.2003-031804. PMID 15001594.
  79. ^ Petridou, E; Mantzoros, C; Dessypris, N; Koukoulomatis, P; Addy, C; Voulgaris, Z; Chrousos, G; Trichopoulos, D (2003). "Plasma adiponectin concentrations in relation to endometrial cancer: A case-control study in Greece". The Journal of Clinical Endocrinology & Metabolism. 88 (3): 993–7. doi:10.1210/jc.2002-021209. PMID 12629074.
  80. ^ Chou, Sharon H; Tseleni-Balafouta, Sofia; Moon, Hyun-Seuk; Chamberland, John P; Liu, Xiaowen; Kavantzas, Nikolaos; Mantzoros, Christos S (2010). "Adiponectin Receptor Expression in Human Malignant Tissues". Hormones and Cancer. 1 (3): 136–45. doi:10.1007/s12672-010-0017-7. PMC 10358112. PMID 21761356. S2CID 25534153.
  81. ^ Ko, Byung-Joon; Park, Kyung Hee; Mantzoros, Christos S (2014). "Diet patterns, adipokines, and metabolism: Where are we and what is next?". Metabolism. 63 (2): 168–77. doi:10.1016/j.metabol.2013.11.004. PMID 24360751.
  82. ^ Park, Kyung Hee; Zaichenko, Lesya; Peter, Patricia; Davis, Cynthia R; Crowell, Judith A; Mantzoros, Christos S (2014). "Diet quality is associated with circulating C-reactive protein but not irisin levels in humans". Metabolism. 63 (2): 233–41. doi:10.1016/j.metabol.2013.10.011. PMC 4373656. PMID 24315778.
  83. ^ Mantzoros, Christos S; Sweeney, Laura; Williams, Catherine J; Oken, Emily; Kelesidis, Theodoros; Rifas-Shiman, Sheryl L; Gillman, Matthew W (2010). "Maternal diet and cord blood leptin and adiponectin concentrations at birth". Clinical Nutrition. 29 (5): 622–6. doi:10.1016/j.clnu.2010.03.004. PMC 2916023. PMID 20363059.
  84. ^ Tsiodras, Sotiris; Poulia, Kalliopi-Anna; Yannakoulia, Mary; Chimienti, Sonia N; Wadhwa, Sanjivini; Karchmer, Adolf W; Mantzoros, Christos S (2009). "Adherence to Mediterranean diet is favorably associated with metabolic parameters in HIV-positive patients with the highly active antiretroviral therapy–induced metabolic syndrome and lipodystrophy". Metabolism. 58 (6): 854–9. doi:10.1016/j.metabol.2009.02.012. PMC 2829239. PMID 19375132.
  85. ^ Fung, T. T; Rexrode, K. M; Mantzoros, C. S; Manson, J. E; Willett, W. C; Hu, F. B (2009). "Mediterranean Diet and Incidence of and Mortality from Coronary Heart Disease and Stroke in Women". Circulation. 119 (8): 1093–100. doi:10.1161/CIRCULATIONAHA.108.816736. PMC 2724471. PMID 19221219.
  86. ^ Yannakoulia, Mary; Yiannakouris, Nikos; Melistas, Labros; Kontogianni, Meropi D; Malagaris, Ioannis; Mantzoros, Christos S (2008). "A dietary pattern characterized by high consumption of whole-grain cereals and low-fat dairy products and low consumption of refined cereals is positively associated with plasma adiponectin levels in healthy women". Metabolism. 57 (6): 824–30. doi:10.1016/j.metabol.2008.01.027. PMID 18502266.
  87. ^ Mantzoros, C. S; Williams, C. J; Manson, J. E; Meigs, J. B; Hu, F. B (2006). "Adherence to the Mediterranean dietary pattern is positively associated with plasma adiponectin concentrations in diabetic women". The American Journal of Clinical Nutrition. 84 (2): 328–35. doi:10.1093/ajcn/84.1.328. PMID 16895879.
  88. ^ http://www.metabolismjournal.com/[full citation needed][permanent dead link‍]
  89. ^ "Coherus BioSciences - A Biosimilar Therapeutics Developer".
  90. ^ "Coherus Bio's CHS-131 shows positive effect in mid-stage MS study". 28 June 2016.
Retrieved from "https://wiki.riteme.site/w/index.php?title=Christos_Socrates_Mantzoros&oldid=1261263451"